AGENDA
APRIL 1-4, 2024
WALTER E CONVENTION CENTER WASHINGTON DC
Washington D.C., 1 - 4 April 2024
Schedule
Create your personal agenda –check the favourite icon
GLOBAL HEALTH mABs [M2]
Public-Private collaboration for accessible infectious disease mAbs in LMICs
There are significant gaps in mAbs access and availability in LMICs. Viable models, commercial incentives and pathways to afford access are currently not in place. Find out how Public-Private collaboration will be needed to bridge this gap...
Co-organized by: MPP, IAVI, Unitaid and Wellcome
Goal of session: To foster mAb developer engagement to understand the barriers and define the incentives and enablers that would facilitate affordable access to mAbs in LMICs.
Target audience: those involved in the development, manufacturing, supply, regulation, and procurement of monoclonal antibodies.
10:00 Introduction
Carmen Pérez Casas, Strategy Senior Lead/PPPR Head, Unitaid
10:20 Panel: Challenges and opportunities: What are the barriers and unique considerations for mAbs accessibility/availability in LMICs? What advancements have recently been achieved and how can they be further leveraged for infectious disease mAbs?
Moderator: Shelly Malhotra, Executive Director, Global Access, IAVI
11:20 Panel: Industry perspectives on a path towards access and the role of global health stakeholders
Moderator: Esteban Burrone, MPP
12:20 Wrap up/Closing remarks
Pete Gardiner, Wellcome
Biodefense & Preparedness
Vaccine Technology [M1]
Senior Representative, InDevR
ANTIMICROBIAL RESISTANCE - Role of vaccines, mABs, phages and antibiotics [F2]
A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?
RNA - From vaccines to therapeutics
How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?
Vaccine Delivery [A1]
Senior Representative, Vaxxas
Senior Representative, Mylife Technologies
Global Health & NTDs [A2]
Create your personal agenda –check the favourite icon
Chair's Opening Remarks
Opening Keynote Address: Female pioneers in developing and implementing lifesaving vaccines
·The journey of turning mRNA and protein based vaccines into life-saving vaccines – what else can they do for us in future?
·How do we identify and nurture the next platform that could save more lives and prevent the next pandemic?
·How will government agencies become more nimble and improve its communications with the public?
·How do we ensure more female leadership and diversity in public health?
Keynote panel: What is the end-to-end life cycle of pandemic vaccines – what do we need to do before, during and after?
·What are the synergistic differences between BARDA and HERA?
·What did we learnt from COVID and how do we plan to fix the issues we encountered?
·How will we manage stockpiles more efficiently and fairly?
·What kind of regulatory flexibility and framework is in place to support pandemic vaccines?
·How do we exit out of EUAs to fully approved vaccines rapidly to get the coverage we want?
Keynote panel: The priority list review – What is our global strategy to priority pathogens and what about the neglected diseases?
·Which pathogens need more research and which need to be developed by manufacturers?
·What about the AMR and neglected diseases lists? Where does that fit?
·Do we have the right strategy to enable us to create the next pandemic vaccine even faster than COVID? Prototype families and platformed based pandemic preparedness models
·How do we interpret the lists for vaccine and or mABs development?
Keynote panel: Paediatric immunisation and disease prevention in RSV
·Use of mABs and vaccines in Infants and Children – which should be use and when?
·Future of mABs in global accessibility and cost-effectiveness
Networking Break
Join us in the exhibition hall (level 3) for:
1:10 – 2:30 1-2-1 Partnering
1:30 – 2:20 Start-up pitches
2:00 – 2:30 Poster Presentations
Keynote: Recent updates on correlates of vaccine-induced protection
·Correlates for vaccines against RSV, CMV and COVID
Keynote panel: Implementing vaccine manufacturing in Africa: Transitioning from manufacturing capability to long term sustainability
·Now we’ve built local manufacturing – is it sustainable?
·Are these decentralized manufacturing hubs working and is the infrastructure also in place to support it?
·How will African producers start matching the multinational manufacturers in production? The role of international and national collaborations
·The need for regulatory strengthening and infrastructure
·How do we ensure vaccine acceptability and uptake of vaccines manufactured from Africa?
Keynote panel: Gaps in Adult Immunization – the next frontier: What is our strategy for better disease prevention and control?
·As the adult vaccination choices get more crowded, what are our implementation strategies and key challenges?
·How do we navigate current ACIP recommendations for best vaccine uptake of RSV?
·How will that impact other new adult vaccines reaching the market?
·Co-administrating vaccines vs combination vaccines – how do we evaluate these?
Keynote panel: Defining and developing broadly protective vaccines
·How do we develop and evaluate the effectiveness second/next generation vaccines?
·Lesson learned in universal flu vaccine efforts
·What developments have been made towards broadly protective vaccines?
Pre-award Networking Drinks
Sponsored by Tekton Research
Chair’s Closing Remarks and Close of Congress Day 1
Gala Dinner & 16th Annual ViE Awards Ceremony
Only those who have paid for the ViE admission can attend.
Create your personal agenda –check the favourite icon
Chair's opening remarks
Panel: Vaccine manufacturing insights from Asia: Strengthening vaccine production capacity and capabilities
- Lessons from the rapid scale up of production capacity to meet pandemic vaccine demand and how we maintain these capabilities post-pandemic.
- How do we stimulate global collaboration between Asia and the rest of the world?
- Strengthening of regulatory systems and alignment between countries
- What is Asia’s appetite in introducing new technologies into their manufacturing capabilities?
Chair's Opening Remarks
Chair's Opening Remarks
Panel: The future of COVID-19 and respiratory vaccinations in combination
-The future of COVID-19 vaccinations: combined annual shots for a seasonal disease with flu and RSV?
-How do we compare the effectiveness of combined respiratory vaccines?
Panel: The future of COVID-19 vaccinations. Should we be developing broadly protective antigens or combinational vaccines?
-The future of COVID-19 vaccinations: annual shots for a seasonal disease?
-How have our variant specific bivalent COVID vaccines performed during the fall?
-How do we compare the effectiveness of combined respiratory vaccines?
What is the burden and uptake for RSV vaccines?
- Updates, epidemiology and vaccine fatigue
- What is the role of mAbs and vaccines for RSV protection?
- How to we ensure better global health accessibility of RSV vaccines?
The future of global health: How to Advance detection and response capacity for Emerging & Re-emerging Pathogens in Africa & LMICs
- Public health preparedness
- Rapid pathogen identification and proactive surveillance systems
Decentralized trial solutions to improve access and health equity – Title TBC
Senior Representative, Emvenio
Emerging & re-emerging zoonotic diseases: what are our priority pathogens for spill over & pandemic risk?
Panel: Middle East – how did their infrastructure hold during COVID? Case studies and experiences
An agile approach to PBMC collection in Vaccine Trials – Title TBC
Senior Representative, Viroclinics DDL a Cerba Research Company
Immune profiling to Inform Precision Vaccines
Nirsevimab, a monoclonal antibody for protection of all infants from RSV
Pediatric Vaccine Research Panel - Title TBC
Senior Representative, PPD, part of Thermo Fisher Scientific
Panel: What are international agencies and industry doing to promote a One Health approach to global health risks
Panellist to be announced
Leveraging the rollout of COVID-19 vaccines to strengthen pharmacovigilance systems in Africa
Title TBC
Senior Representative, Flourish Research
Viral Vector Vaccine and mRNA Vaccine Development & Manufacturing Platform
Novavax COVID-19 Vaccine: Latest Clinical Trial Updates
Senior representative, Novavax
Comprehensive immunoprofiling & systematic adjuvant comparisons for identifying suitable vaccine: adjuvant pairings
T-cell assays: measuring effectors
Sudan Ebola Virus (SUDV)
In vivo Model Design and Assay Selection to Aid in Progression From Preclinical to Clinical - Title TBC
Senior Representative, Q² Solutions
Development of a clinical-scale process for a universal influenza vaccine candidate – Title TBC
Senior Representative, Emergent Biosolutions
Strengthening Africa’s healthcare system
- National (and international) agencies – PAVM, GAVI, UNICEF, Africa FDA
Predictive translational immunology for mRNA vaccination
Liquid biopsies & ctDNA in treatment response & MRD monitoring
Speaker TBC
Centralized Laboratory Network approaches for SARS-CoV-2 and Future Outbreaks
Updated Strategies for Immune Profiling in Vaccine Development with xMAP Technology – Title TBC
COATSOME® SS Series: Biodegradable Lipid Nanoparticles for mRNA Vaccines with Room Temperature Stability – Title TBC
Reserved for NOF America Corporation
Current development of an mRNA vaccine for RSV
Panel: Progress towards eliminating Malaria
Preparing for and responding to emerging infectious diseases - Title TBC
Senior Representative, ICON plc
Novel cap analogs and modified NTPs to enable therapeutic mRNA development
Navigating the complex study designs of therapeutic vaccines
Senior represntative PPD, part of Thermo Fisher Scientific
Panel: Partnerships between industry and vaccine implementation programs
- What is needed to design tiered pricing for vaccines?
- How is current vaccine supply being planned assured, particularly with LMICs?
- Navigating limited supply of vaccines market availability increases
- How industry and government are working with NGOs and mechanisms like GAVI to make vaccines more accessible
- MIC countries and affordability of vaccine supply programs.
Development of VBI-2901: A Multivalent Pan-Coronavirus Vaccine
Reserved for Dr Dave Anderson, CSO, VBI Vaccines
Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays
Strategies for Improving in vivo Study Data Rigor and Reproducibility
A vaccine for bees: targeting pollinator health for future food security
How can we better leverage the data we have?
- How to get the most out of the data you are generating: moving from passive to active (re)use of data
- The use of computational tools for different aspects of research; how much data is enough to use AI and how does it need to be organized?
- Manifestations, challenges & opportunities from pre-clinical to clinical
RSV for older adults
A PI’s perspective: Using a whole-of-government approach to conducting vaccine clinical trials during the COVID-19 pandemic - Title TBC
Senior Representative, Allucent
Considerations for mRNA Vaccine Development – Title TBC
Senior Representative, Trilink Biotechnologies
Panel: The collaborative role of developing country vaccine manufacturers in global immunization and pandemic preparedness
Elicio Therapeutics: therapeutic mKRAS targeted cancer vaccine
Invited: Robert Connelly, CEO, Elicio Therapeutics
Prevention of Infant RSV Illness with a bivalent RSVPreF Vaccine in Pregnancy
Title TBC
Senior representative, Q2 solutions
Nouscom: off-the-shelf cancer immunotherapy for dMMR/MSI tumours & personalized neoantigen-based cancer vaccine
Unmet needs in RSV vaccines; opportunity for a broader respiratory vaccine
Pre-clinical nanoparticle vaccine candidate targeting Epstein-Barr Virus
Senior Representative, NIH/Merck
Panel: Expedite and Streamline Vaccine Trials in the Post-pandemic Era - Title TBC
Senior Representative, Parexel
Evolving vaccine standards to support quality throughout the product lifecycle: from raw materials to drug product
Next Generation DNA vaccines for ‘One Health’ – Title TBC
Avoiding key material bottlenecks with improved regulatory strategies – title TBC
Vaccines against EBV - Title TBC
Challenges for the availability of vaccines and drugs against infectious diseases: regulatory perspectives
Vaccine development in the post pandemic environment - Title TBC
Syneos Health
Using high dimensional immune profiling in human disease to interrogate individual responses to therapeutic interventions
Update on Novavax Influenza and COVID-Influenza Combination Vaccine
Development of an inactivated EV D68 vaccine using Vero cell platform technology
Advancing DNA Medicines: Clinical Learnings from Candidates Targeting Ebola and Recurrent Respiratory Papillomatosis - Title TBC
Clinical development of Serum Institute's Polysaccharide Conjugate Vaccines with PeliCRM197 – Title TBC
Clinical pipeline updates: Vaccitech
Invited: Bill Enright, CEO, Vaccitech
Evaluating candidate vaccines and Immunotherapeutics against Sudan Ebola Virus
Reserved for UTMB
The future is now- the rise of emerging markets - Title TBC
Senior Representative, PDC CRO
Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Targeting T-cell responses to conserved regions of major viral families to modulate and prevent severe disease
Clinical pipeline updates: Geneos Therapeutics
Utilizing human challenge models to advance vaccine development – Title TBC
Panel: Vaccine development and efforts towards eradicating Chikungunya
High cell density and cost-effective manufacturing of viral vectors
A thermostable film matrix removing cold chain logistics -Title TBC
Senior Representative, Jurata Thin Film
mRNA cancer vaccine & PD-1 antibody combination in NSCLC: how molecular response correlates with OS
Invited: Dr Natalie Vokes, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ensuring clinical availability of vaccine delivery systems, immunostimulators & combined adjuvant systems
Showcase 4: Leveraging Consortia during Preparedness and Response
Senior Representative Advanced Technology International
Intranasal Immunization: Device and Formulation Promises and Challenges
Julie Suman, Vice President Scientific Affairs, AptarPharma
Nektaria Karavas, Global Director of Business Development, Aptar Pharma
Pre-clinical and clinical development, mechanisms and predictive biomarkers, of vaccines and monoclonal antibodies for opioid use disorders and overdose
Clinical pipeline updates: BioNTech
Prof Ilhan Celik / Dr Michael Wenger, Vice President, Clinical Development, BioNTech- TBC
Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines
Reducing protocol deviations and increasing data quality in vaccine trials
Objective selection of virus strains from sequence data for pandemic preparedness – title TBC
Clinical pipeline updates: Gritstone
Avacc 10: An intranasal Outer Membrane Vesicle based subunit vaccine for COVID 19
mRNA-4157 overview: the impact of a cancer vaccine on those with melanoma – Title TBC
Title TBC
Reserved for Novo Nordisk
A rapid response platform for nucleic acid vaccines
Senior Representative, Touchlight
Conducting Clinical Trials in Australia: Advantages and Case Studies – Title TBC
Senior Representative, Acclime Australia
Senior Representative, BioCina
Senior Representative, Paratus Clinical
CDMO Perspective on Global Vaccine Supply: Preparing for next pandemic and booming vaccine innovation – Title TBC
Senior Representative, Wuxi Vaccines
Universal avian influenza vaccines – Title TBC
Development of a broadly protective pan-sarbecovirus nanoparticle vaccine
Panel: What technologies and partnerships is industry investing in?
AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses
Reserved for NEC OncoImmunity AS
Translation & feasibility of immune correlates to the clinical space
Panel: Exploring the future prospects of cancer vaccines
- Exploring the role and prospects of (neo)adjuvant cancer vaccines in the therapeutic landscape: adjuvant versus neoadjuvant, prevention of reoccurrence vs truly therapeutic, value in metastatic disease
- Indications & immune characteristics: hot versus cold tumors & TME
- Is there potential for off-the-shelf vaccines? What might this strategy look like?
High volume clinical trial sample testing – tbc
Senior Representative Microbiologics
Self-assembling in-vivo nano particle vaccines
Panel: Clinical operations overseas
Invited: Caroline Forkin, Head of Clinical Development Programmes and Operations, CEPIProposed speakers: Senior Representative, Africa CDCSenior Representative, WHO
Tackling challenges in the downstream development of viral vectors for CTM production – Title TBC
Senior Representative, IDT Biologika
How do we change the business model for the veterinary industry to rapidly respond to disease outbreaks?
OVX836 first-in-class broad-spectrum influenza vaccine in elderly patients
Senior Representative Osivax
Rapid development of lyophilized VLP-Nucleic acid vaccines – Title TBC
5:40 Investment Panel: how to secure funding for vaccines for global health?
Senior Representative Pappas Capital
More to follow..
Next-generation Influenza vaccines/structural vaccinology for influenza virus
Off-site Networking Drinks
Sponsored by Viroclinics-DDL
Create your personal agenda –check the favourite icon
Chair's Opening Remarks
Chair's Opening Remarks
Multispecific antibodies for infectious diseases: Applications to HIV and SARS-CoV-2
Combinations of vaccines with novel immunomodulatory agents beyond checkpoint inhibitors
So what’s next? Respiratory viruses we need to think about in the future
- How are we approaching new technologies; RSV, Flu, COVID
Pandemic Prepardness
Senior Representative, BioNTech
Antigen screening for Border Disease RNA Vaccines – Title TBC
Panel: How to secure US Government funding
Senior Representative DARPA, Walter Reed Army Institute and ARPA-H
COVAX, what’s next?
- What did we learn from COVAX during COVID and how are we preparing for rapid roll out of vaccines in future pandemics and epidemics?
- Vaccine supply chain considerations for multi stakeholder collaboration and contingency planning for future disease outbreaks.
- Strengthening end-to-end capabilities during non-pandemic periods, to create a resilient ecosystem for future emergency situations.
West Nile Fever Vaccine
Senior Representative, CDC
Improving genetic tools for African swine fever virus to facilitate development of an effective vaccine
New Frontiers in Cancer Vaccine Antigens: AI-Driven Target Discovery for Broader Therapeutic Reach
Senior Representative, Evaxion Biotech A/S
Update on Pneumococcal vaccine
Zika virus: Human challenge models and human development
Improving Clinical Trial Recruitment - Title TBC
Developing a Smart, Digitally Controlled, Fully Integrated Continuous Manufacturing Production Line designed for Pandemic-Level Response
Novel RNA vaccine and nano-adjuvants system for Veterinary Vaccines
Staying in Control: Identifying the right controls for the evolving field of live cell assays - Title TBC
Senior Representative, Eurofins Viracor BioPharma Services
The first antifungal vaccine: from corn to humans
Cutaneous jet injection of naked mRNA for safe and effective vaccination against infectious
Developing Mucosal vaccines for respiratory viruses
Senior Representative, NIH
Phase 1 novel multivalent OspA-based vaccine candidate against Lyme borreliosis
Senior Represenative, Pfizer/Valneva
Title TBC
Senior Representative, Cepheid
Nanoscale liposomal GD3 vaccine stimulates an immune response in naturally occuring cancers in canines
Title TBC
Senior Representative AAHI
Innovations & Technologies for the Last Mile
Serological assays for respiratory viruses (FLU, SARS-CoV-2 & RSV)
Senior Representative, VisMederi
Networking Break
The development of multi-epitope, nanoparticle-based vaccine candidates that could provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses
Overcoming original antigenic sin
- Molecular determinants of antigenic evolution & immunological mechanisms of OAS
- Implications on vaccine design & immunization strategies: combined resp virus vaccines?
- Strategies to overcome or minimize impacts of OAS
GD3 and GD2 gangliosides serve as tissue-agnostic cancer antigens in a nano-scale liposomal cancer vaccine in a true disease model of osteosarcoma and melanoma
Embedding a new influenza vaccine into health care practice
Senior representative CDC
Panel: Dengue – Challenges and opportunities in Vaccine development
Panel: How we teach about vaccines and vaccination
Early stage clinical results from a novel preventative breast cancer vaccine – Title TBC
Title TBC
Senior Representative, Jurata Thin Film
Vaccine induction of broadly-specific antibody and T-cell responses to combat SARS-CoV-2 variation
Next-Generation approaches to respiratory infections in older adults
Senior Representative, Utrecht University
Plenary chair’s opening remarks
Keynote Panel: Escalating infections: the impact of climate change and natural disasters on infectious diseases
·Which world vaccination programs are under threat?
·The devasting impact on infectious diseases reaching far beyond its origins
·How climate change increases pandemic risk and spillover between humans and animals
·The need to invest in strong health systems now to stay resilient to the inevitable complex changes that climate change will bring
Keynote closing panel: The impact on AI to protecting public health threats and behaviour
·The role of AI in public health, current and future
·Could AI have helped us to prevent a pandemic? Expanding vaccine libraries, predicting strain drifts, monitoring surveillance, vaccine design
·Success, limitations and risks of AI
·What is the evolving regulatory landscape on AI?
Chair Closing Remarks and End of Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events